[Does oncology change its paradigm? The challenge of agnostic approval of new therapies.]

Area of Science:

• Oncology
• Pharmacogenomics
• Health Systems Science

Background:

• Traditional oncology drug approvals are disease-specific.
• Recent regulatory shifts approve therapies based on biomarker data, irrespective of cancer site.
• This represents a paradigm shift towards a
• Purpose of the Study
• Main Methods
• Main Results
• Conclusions

Discussion:

• The "mutational model" approves drugs based on activity against specific driver mutations, regardless of primary disease site, age, or gender.
• This paradigm shift necessitates proactive adaptation within the healthcare system.
• Anticipating these changes is crucial for maintaining appropriateness and economic sustainability of cancer therapies.

Key Insights:

• Drug approval is increasingly based on molecular targets (mutations) rather than solely on anatomical tumor location.
• This approach allows for broader application of targeted therapies across diverse cancer types.
• Real-time data gathering and evidence generation are essential for system governance.

Outlook:

• Multidisciplinary networks of oncologists, pathologists, epidemiologists, and health decision-makers are vital.
• Updated disease registries are crucial for supporting these networks.
• Implementing these strategies will ensure effective governance and sustainability of novel cancer treatments.